# US 2021/0172949 A1 · Methods and materials for the detection of latent tuberculosis infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172949 A1
- Document ID: US20210172949A1
- Status: Published application
- Kind: A1
- Application number: 16/771,132
- Filed: 2018-12-21
- Published: 2021-06-10
- Earliest claimed: 2017-12-22
- Assignees: Imperial College Innovations Limited
- Applicants: Imperial College Innovations Limited
- Inventors: Ajit Lalvani; Alice Halliday
- Web page: https://patentgrep.com/patent/US20210172949A1

## CPC

- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/56972: {White blood cells}
- G01N 33/6866: {Interferon}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There are provided methods of determining the latent tuberculosis (TB) infection status in an individual comprising: (i) providing a sample comprising T-cells; (ii) exposing, the sample of (i) to one or more TB antigens; (iii) identifying T-cells in the sample that are CD4 positive and secrete IFN-γ in response to TB antigens; (iv) identifying those cells of (iii) which are also HLA-DR positive; and optionally (v) calculating the cells identified in (iv) as a percentage of those identified in (iii); wherein the identification of cells in (iv) and/or the percentage of cells calculated in (v) correlates to latent TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously. There are also provided compositions and kits for use in such methods.

## Claims

### Claim 1

A method of determining the latent tuberculosis (TB) infection status in an individual comprising:
(I) providing a sample comprising T-cells:
(ii) exposing the sample of (i) to one or more TB antigens;
(iii) identifying T-cells in the sample that are CD4 positive and secrete IFN-γ in response to TB antigens;
(iv) identifying those cells of (iii) which are also HLA-DR positive, and optionally
(v) calculating the cells identified in (iv) as a percentage of hose identified in (iii);
wherein the identification of cells in (iv) and/or the percentage of cells calculated in (v) correlates to latent TB infection status of the individual, and wherein steps (iii) and (iv) can be carried out either sequentially or simultaneously.

### Claim 2 (depends on 1)

The method of claim 1 wherein the latent TB infection status determined by the method corresponds to the risk of the latent TB infection progressing to an active TB infection.

### Claim 3 (depends on 2)

The method of claim 2 wherein the risk of the latent TB infection progressing to an active TB infection is proportional to the percentage value calculated in step (v) of the method.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3 wherein there is a high risk of the latent TB infection progressing to an active TB infection when the percentage calculated in step (v) is greater than a cut off value.

### Claim 5 (depends on 4)

The method of claim 4 wherein the cut off value is a value between 10% and 50%, between 20% and 40%, between 25% and 40%, between 20% and 35%, between 25% and 35%, or between 25% and 30%.

### Claim 6

The method of any previous claim wherein the latent TB infection status determined by the method corresponds to the amount of time elapsed since the individual was originally infected with TB.

### Claim 7 (depends on 6)

The method of claim 6 wherein the time elapsed since the individual was originally infected with TB is inversely proportional to the percentage value calculated in step (v).

### Claim 8

The method of any previous claim wherein the cells identified in step (iii) are additionally CD3 positive.

### Claim 9

The method of any previous claim wherein the cells identified in step (iii) are additionally CD8 negative.

### Claim 10

The method of any previous claim wherein the T-cells identified in step (iii) are identified as live T-cells, preferably by use of a dead cell marker.

### Claim 11

The method of any previous claim wherein an additional step (ii-a) is performed between steps (ii) and (iii) to block the release of cytokines, preferably by adding a golgi-inhibitor.

### Claim 12

The method of any previous claim wherein the sample is a blood sample (preferably a PBMC sample), a bronochoalveolar lavage (BAL) sample or a cerebral spinal (CBF) sample.

### Claim 13

The method of any previous claim wherein steps (iii) and/or (iv) are performed by multi-parameter flow cytometry.

### Claim 14

The method of any previous claim wherein an additional step is first performed in order to determine that the sample is obtained from an individual infected with latent TB.

### Claim 15 (depends on 14)

The method of claim 14 wherein the additional step is performed using ELISpot platform, an interferon gamma release assay (IGRA) and/or a tuberculin skin test.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15 wherein there is an absence of clinical and/or radiological features of active TB in the individual.

### Claim 17

A composition comprising a plurality of antibodies or antigen-binding fragments thereof that binds to each of CD4, IFN-γ and HLA-DR and wherein the plurality comprises antibodies or antigen-binding fragments thereof that are individually specific for each of CD4, IFN-γ and HLA-DR.

### Claim 18 (depends on 17)

The composition of claim 17 wherein the plurality of antibodies or antigen-binding fragments thereof additionally binds to CD3 and additionally comprises antibodies or antigen-binding fragments thereof that are individually specific for CD3.

### Claim 19 (depends on 17, 18)

The composition of claim 17 or 18 wherein the plurality of antibodies or antigen-binding fragments thereof additionally binds to CDB and additionally comprises antibodies or antigen-binding fragments thereof that are individually specific for CD8.

### Claim 20 (depends on 17, 18, 19)

The composition of any one of claims 17-19 wherein the plurality of antibodies or antigen-binding fragments thereof additionally binds to a live or dead cell marker and additionally comprises antibodies or antigen-binding fragments thereof that are individually specific for a live or dead cell marker.

### Claim 21 (depends on 17, 18, 19, 20)

The composition of any of claims 17-20 wherein the antibody or antigen-binding fragments thereof is selected from antibody or antigen-binding fragment thereof is selected from the group consisting of Fv fragments, soFv fragments, Fab, single variable domains and domain antibodies.

### Claim 22 (depends on 17, 18, 19, 20, 21)

The composition of any one of claims 17 to 21 wherein the antibodies or antigen-binding fragments thereof with a particular specificity are separately detectable to those with a different specificity.

### Claim 23 (depends on 17, 18, 19, 20, 21, 22)

The composition of any one of claims 17 to 22 wherein the antibodies or antigen-binding fragments thereof are visually detectable.

### Claim 24 (depends on 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 17 to 23 wherein the antibodies or antigen-binding fragments thereof are labelled (e.g. with a fluorescent label).

### Claim 25 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The composition of claims 17 to 24 for use in determining the risk of a latent TB infection progressing to an active TB infection.

### Claim 26 (depends on 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 17 to 24 for use in treating an active TB infection wherein the use comprises identifying if a subject is at risk of developing an active TB infection and subsequently administrating the most appropriate preventative treatment for that infection.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of treating a subject determined to be at risk of developing an active TB infection comprising:
(a) conducting the method of any of claims 1 to 16; and
(b) administrating the most appropriate preventative treatment to the subject depending on the outcome of the step (a).

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of stratifying an individual for preventative treatment of active TB infection comprising:
(a) conducting the method of any of claims 1 to 16; and
(b) stratifying Individuals determined to be at risk of developing active TB infection for the most appropriate preventative treatment depending on the outcome of the step (a).

### Claim 29

A kit for determining tuberculosis (TB) infection status in an individual comprising:
(i) a composition comprising a plurality of antibodies or antigen-binding fragments thereof that binds to each of CD4, IFN-γ and HLA-DR and wherein the plurality comprises antibodies or antigen-binding fragments thereof that are individually specific for each of CD4, IFN-γ and HLA-DR;
(ii) instructions for use.

### Claim 30 (depends on 27)

A kit as claimed in claim 27 wherein the plurality of antibodies or antigen-binding fragments thereof of the composition of (i) additionally binds one or more of CD3 and CD8 and additionally comprises antibodies or antigen-binding fragments thereof that are individually specific for each of one or more of CD3 and CD8.

### Claim 31 (depends on 29, 30)

A kit as claimed in any one of claims 29 to 30 additionally comprising one or more TB antigens, a live and/or dead cell discriminator, a fixing and/or permeabilization kit; a golgi inhibitor; and/or a positive control.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 31)

The method of any of claims 1-16 or the kit of claim 31 wherein the TB antigens comprise PPD and/or RD-1 antigens.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 31, 32)

The method of any of claims 1-16 or 32 or the kit of claim 31 or 32 wherein the TB antigens comprise one or more of ESAT-6, CFP-10, Rv3615c, and Rv3879c.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 29, 30, 31, 32, 33)

Use of a kit as claimed in any one of claims 29 to 33 the method of any of claims 1 to 16.

### Claim 35

A method, composition, kit or use substantially as described herein with reference to the Examples and Figures.
